ACC 2023: Late-Breaking Science Video Collection

Published: 06 March 2023

  • Views:

    Views Icon 5660

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Our regular review series View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provides a critical analysis of the late-breaking and featured science results and spotlights impactful data. 

 

For a deeper look into the key clinical trial data revealed at ACC 23, Dr Harriette Van Spall (McMaster University, Hamilton, CA) interviews the principal investigators in her regular Late-Breaker Discussion Series. 

 

For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research. 

More from this programme

Part 1

Late-Breaker Discussion Series

Host, Dr Harriette Van Spall is joined by principle investigators for discussion on selected late-breaking trials.  

5 sessions
The CLEAR-Outcomes Trial with Dr Harriette Van Spall & Dr Steven Nissen Watch now
The REVIVED-BCIS2 Viability Study with Dr Harriette Van Spall, Dr Divaka Perera & Dr Peter O'Kane Watch now
The BETTER-CARE HF Trial with Dr Harriette Van Spall & Dr Amrita Mukhopadhyay Watch now
The COORDINATE-Diabetes Trial with Dr Harriette Van Spall, Dr Neha J Pagidipati & Dr Christopher B Granger Watch now
The BIOVASC Trial with Dr Harriette Van Spall & Prof Roberto Diletti Watch now

Part 2

Expert Interviews

11 sessions
Statins to Protect Heart During Cancer Treatment: The STOP-CA Trial Watch now
RENOVATE-COMPLEX-PCI: IVUS Vs OCT Optimisation in Complex PCI Watch now
Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study Watch now
Mini-Thoracotomy Vs Sternoctomy for Degenerative Valve Disease: The UK Mini-Mitral Study Watch now
TAVR in Low-Risk Aortic Stenosis Patients: 3-Year Results From the Evolut Low Risk Trial Watch now
Pulsed Field Ablation in Persistent Atrial Fibrillation Patients: The PULSED AF Trial Watch now
MK-0616: Oral PCSK9 inhibitor In Hypercholesterolemia Patients Watch now
Evaluation of the Mechanism of Benefit for Dapagliflozin in HFpEF Watch now
BMAD Trial: μCor in Ambulatory Decompensated Heart Failure Watch now
The STELLAR Phase II Trial: Sotatercept in Patients With Pulmonary Arterial Hypertension Watch now
Inflammatory Risk from Statin-Treated Patients: Findings from PROMINENT, REDUCE-IT and STRENGTH Watch now

Part 3

View from the Thoraxcenter

In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC 2023. 

2 sessions
ACC.23 Late-breaking Science Wrap Up Watch now
What's Hot at ACC.23? Late-breaking Science Preview Watch now

Part 4

Highlights Reviews

4 sessions
Interventional Late-breaking Highlights with Dr Mirvat Alasnag & Dr Khaled Al-Shaibi Watch now
Lipid Management & the CLEAR Trial with Dr Erin Michos Watch now
Obesity Management Strategies in 2023 with Dr Harold Bays Watch now
ACC.23 President Interview with Dr B Hadley Wilson Watch now

Part 5

Behind the Heart

Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.

7 sessions
Dr Akowuah: Cardiovascular Research & Message for Early-Career Researchers Watch now
Dr Kini: Asking Questions & Her Motivation to Do Research on Plaque Watch now
Drs Day, Lambert & Ackerman: Passion For Cardiovascular Research & Advice for Researchers Watch now
Dr Verma: Passion for Electrophysiology & His Advice For Young Researchers Watch now
Dr Wilson on Why Did He Choose Cardiology & His Advice for Early-career Faculty Watch now
Dr Hahn: Innovative Areas of Cardiovascular Science in 2023 Watch now
Dr Forrest: Structural Heart Innovations and Advice to Young Researchers Watch now

About the episode

Principle investigator of YELLOW III, Dr Annapoorna Subhash Kini (Mount Sinai Hospital, US) joins us to talk about the study that assessed the effect of evolocumab (Repatha) on coronary plaque morphology using intravascular imaging and gene expression analysis of peripheral blood mononuclear cells (PBMC) in 140 patients with stable CAD on maximally tolerated statin therapy (NCT01837823). 

The study showed that more intensive lipid lowering with addition of evolocumab for 26 weeks resulted in significant and substantial increase in the minimum FCT by OCT, reduction in NIRS maxLCBI4mm and reduction in atheroma volume by IVUS in angiographically non-obstructive lesions.

Questions:
1. What prompted the YELLOW studies? 
2. What are the baseline characteristics of the enrolled patients?
3. What are the key findings presented at ACC?
4. What are the potential implications for patient care?
 

Recorded on-site at ACC.23, New Orleans. 

Faculty Biographies

Annapoorna Kini

Annapoorna Kini

The Mount Sinai Hospital

Annapoorna Kini, is an endowed Zena and Michael A Wiener Professor of Medicine, Director of Cardiac Catheterization Laboratory at The Mount Sinai Medical Center, Program Director of Interventional Cardiology Fellowship and Director of Structural Heart Intervention Program. Annapoorna is an international leader in the field of percutaneous coronary intervention and heart valve therapy.

Annapoorna is internationally acclaimed for her special expertise in performing complex and high-risk interventional cases, especially in chronic total occlusion, calcific and bifurcation lesions. She has extensive experience with the techniques of mitral, aortic balloon valvuloplasty, and septal (alcohol) ablation for the treatment of obstructive hypertrophic cardiomyopathy. She has been among the first interventional cardiologists in the country to use transcutaneous aortic valve implantation procedure in the treatment of patients with aortic stenosis and performs MitralClip…

View full profile

Comments

You must be to comment. If you are not registered, you can register here.